CTI to conduct phase II study of pixantrone in metastatic breast cancer through NCCTG

[News]

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

More... (http://www.news-medical.net/news/20100513/CTI-to-conduct-phase-II-study-of-pixantrone-in-metastatic-breast-cancer-through-NCCTG.aspx)